Opportunity
Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional) PAR-20-225
Award Info:
Applicants must meet the definition of an Early Stage Investigator (ESI): a new investigator (defined as a PD/PI who has not completed successfully for a significant NIH independent research award) who is within 10 years of completing his/her terminal research degree or is within 10 years of completing medical residency (or the equivalent). Applicants also must hold an independent research position at a domestic (U.S.) institution as of September 1 of the fiscal year of the competition.
Application budgets are limited to $300,000 in Direct Costs each year for up to five years, plus applicable Facilities and Administrative (F&A) costs to be determined at the time of award.
Description:
The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field. The Genetics or Epigenetics of Substance Abuse Avenir Award program supports early stage investigators proposing highly innovative studies that open new areas of research for the genetics or epigenetics of addiction. These may be novel methods or approaches that can potentially be applied to the analysis of the genetics or epigenetics of addiction. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field of genetics or epigenetics.